AbbVie's Parkinson’s Therapy Rejected by U.S. FDA for Late-Stage Motor Fluctuations

Gelonghui June 25 | AbbVie Inc. said on Tuesday that the U.S. Food and Drug Administration (FDA) has rejected the company's application for the market approval of its therapy to treat motor fluctuations in adult patients with advanced Parkinson's disease.